CCCC Stock Forecast: C4 Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for C4 Therapeutics, Inc. is $11. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 65 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores C4 Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (94): Sales and profits are climbing, and climbing faster than before.
Volatility (24): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CCCC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CCCC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Nov 2026 | Guggenheim | Maintains | Buy | $7.00 → $6.00 |
| 28 Oct 2026 | Lake Street | Initiates | Buy | $11 |
| 9 Oct 2026 | JP Morgan | Initiates | Overweight | $10 |
| 1 June 2026 | Evercore ISI Group | Maintains | Outperform | $7.00 → $12 |
| 27 Feb 2026 | Barclays | Maintains | Overweight | — |
| 23 Feb 2026 | Brookline Capital | Maintains | Buy | — |
| 17 Dec 2025 | Barclays | Maintains | Overweight | — |
| 2 Dec 2025 | TD Cowen | Initiates | Buy | — |
| 23 Sept 2025 | Barclays | Maintains | Overweight | — |
| 23 Sept 2025 | Wells Fargo | Maintains | Overweight | — |
| 22 Sept 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 17 Sept 2025 | Barclays | Initiates | Overweight | — |
| 15 Sept 2025 | Stephens & Co. | Upgrade | Overweight | — |
| 4 Sept 2025 | Guggenheim | Initiates | Buy | — |
| 19 Dec 2024 | Wells Fargo | Upgrade | Overweight | — |
| 18 Nov 2024 | Stephens & Co. | Initiates | Equal-Weight | — |
| 6 Aug 2024 | BMO Capital | Reiterates | Outperform | — |
| 9 May 2024 | Stifel | Maintains | Buy | — |
| 9 May 2024 | Wells Fargo | Maintains | Equal-Weight | — |
| 26 Feb 2024 | Morgan Stanley | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CCCC.
This page is one stock. Monday covers all of them.
CCCC appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CCCC vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, C4 Therapeutics, Inc. returned +4.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CCCC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 10.1×
- Price / book
- 1.4×
- EV / EBITDA
- —
Cheaper than 12% of US stocks
Cheaper than 56% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −47.6%
- Return on assets
- −21.3%
- Dividend yield
- —
Higher than 22% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
C4 Therapeutics, Inc. has a market value of $320.4M and an enterprise value of $170.3M.
Revenue in the twelve months to 30 June 2026: $35.0M. The latest quarter grew 2.8% year on year.
Net income over the same four quarters: −$101.4M, a −289.4% net margin.
Diluted earnings per share, trailing twelve months: −$1.00.
Free cash flow in the twelve months to 30 June 2026: −$85.4M.
C4 Therapeutics, Inc. spent $238K on share buybacks in the twelve months to 30 June 2026.
C4 Therapeutics, Inc. employs 104 people — $337K of revenue per employee.
Data provided by Twelve Data
CCCC and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CCCC’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own C4 Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CCCC
What is the CCCC stock price forecast for 2026-2027?
The median 12-month analyst price target for C4 Therapeutics, Inc. is $11, with estimates ranging from $6 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CCCC stock a buy right now?
Of the 9 analysts covering C4 Therapeutics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks C4 Therapeutics, Inc. 65 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CCCC?
As at 21 Nov 2026, C4 Therapeutics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).
Will CCCC stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts is $11, and Ticker Nerd's factor model ranks C4 Therapeutics, Inc. 65 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CCCC stock forecast for 2030?
No analyst covering C4 Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CCCC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $30 over the next 12 months.
How has CCCC stock performed over the past year?
C4 Therapeutics, Inc. returned +4.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does C4 Therapeutics, Inc. do?
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation, a drug-development approach designed to eliminate disease-causing proteins rather than only blocking their activity. The company develops small-molecule medicines built on its proprietary TORPEDO platform, which is used to design and optimize degraders for difficult-to-treat diseases.
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation, a drug-development approach designed to eliminate disease-causing proteins rather than only blocking their activity. The company develops small-molecule medicines built on its proprietary TORPEDO platform, which is used to design and optimize degraders for difficult-to-treat diseases. Its current pipeline is centered on oncology, with programs aimed at cancers such as multiple myeloma, lymphoma, melanoma, colorectal cancer, and non-small cell lung cancer. C4 Therapeutics also works through strategic collaborations with other biopharmaceutical companies to expand the reach of its technology and advance new therapeutic candidates. Based in Watertown, Massachusetts, C4 Therapeutics plays a specialized role in the biotechnology market by advancing a next-generation therapeutic modality that seeks to address targets and pathways not readily handled by traditional small-molecule drugs.
CEO Mr. Andrew J. Hirsch M.B.A. · 104 employees · United States · https://www.c4therapeutics.com